Casdin Capital’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

Casdin Capital’s Portfolio ORTX Stock Details ORTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-257,500	Closed	-$5.92M	–	59
2021 Q3	$5.92M	Sell	257,500 -64,043	-20%	-$1.91M	0.15%	48
2021 Q2	$14.1M	Hold	321,543	–	–	0.36%	39
2021 Q1	$23.3M	Buy	+321,543	New	+$22.8M	0.7%	29
2020 Q4	–	Sell	-187,000	Closed	-$7.69M	–	56
2020 Q3	$7.69M	Buy	187,000 +22,000	+13%	+$1.14M	0.34%	39
2020 Q2	$9.9M	Buy	165,000 +67,500	+69%	+$6.18M	0.59%	35
2020 Q1	$7.34M	Buy	97,500 +15,500	+19%	+$1.79M	0.78%	33
2019 Q4	$11.3M	Buy	82,000 +51,000	+165%	+$6.2M	1.04%	28
2019 Q3	$3.68M	Buy	31,000 +21,000	+210%	+$2.93M	0.38%	30
2019 Q2	$1.4M	Buy	+10,000	New	+$1.76M	0.13%	31

Other funds holding ORTX

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Casdin Capital's ORTX Position: Q4 2021 in Review

Casdin Capital sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q4 2021, closing a stake of 257,500 shares — an estimated $5.92M sold.

Casdin Capital first reported a position in ORTX in Q2 2019 and held it in 9 quarters. The position peaked at $23.3M in Q1 2021. 72 funds tracked by Wall St. Rank hold ORTX as of Q4 2021.

Casdin Capital reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q4 2021 after selling out during the quarter.
Casdin Capital sold 257,500 Orchard Therapeutics plc American Depositary Shares shares in Q4 2021, an estimated $5.92M.
Casdin Capital first reported a position in Orchard Therapeutics plc American Depositary Shares in Q2 2019 and held it in 9 quarters.
Casdin Capital's Orchard Therapeutics plc American Depositary Shares position peaked at $23.3M in Q1 2021.
72 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q4 2021.

Based on Casdin Capital's 13F filing for Q4 2021, filed 14 Feb 2022.